Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Virazole in hospitalized COVID-19 patients with respiratory distress
NCT04551768Phase 1Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
Phase 1, open-label trial of ribavirin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Clinical Status Severity Rating at 7 days. Started Feb 2021; status: completed.
02
Drugs
ribavirin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04551768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551768.